Full-Time
Posted on 5/15/2025
Provides genetic testing for rare diseases
$31.25 - $33.65/hr
Mid, Senior
United States
GeneDx specializes in genetic testing to diagnose rare diseases by analyzing a patient's DNA for mutations linked to health conditions. The company collects DNA samples through cheek swabs, blood, or other specimens and sequences them to identify genetic variations. With over 300,000 clinical patient exomes sequenced, GeneDx provides rapid testing services, such as GenomeXpress and XomeDx Xpress, delivering results in as little as seven days. This quick turnaround is crucial for timely diagnosis and treatment, which can improve patient outcomes and reduce healthcare costs. Unlike many competitors, GeneDx focuses on personalized medicine and offers digital Patient Letters to help patients and families understand their genetic information. The company's goal is to lead in clinical genomics by providing accurate and efficient genetic testing services that support healthcare providers and enhance patient care.
Company Size
501-1,000
Company Stage
IPO
Headquarters
Gaithersburg, Maryland
Founded
2000
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Unlimited Paid Time Off
401(k) Retirement Plan
Employee Discounts
Voluntary benefits
GeneDx (Nasdaq: WGS) today announced the successful completion of its acquisition of Fabric Genomics, a pioneer in AI-powered genomic interpretation.
NEW YORK - GeneDx said Wednesday that it plans to acquire Fabric Genomics for $33 million in cash with the potential consideration rising to $51 million if certain milestones are met.
What You Should Know:– GeneDx, a company focused on improving health outcomes through genomic insights, has announced its plans to acquire Fabric Genomics, a pioneer in AI-powered genomic interpretation.– The acquisition aims to position GeneDx at the forefront of the next phase of genomic medicine, characterized by decentralized testing with centralized intelligence. Following the closing of the acquisition, Fabric Genomics will initially operate independently while benefiting from GeneDx’s commercial support to accelerate its expansion.AI-Powered Genomic InterpretationThe acquisition is motivated by the increasing accessibility of DNA sequencing, which allows for the decoupling of interpretation services from physical laboratories. This decoupling is expected to provide greater flexibility in integrating genomic information into the workflows of healthcare providers and health systems, both in the U.S. and globally. Fabric Genomics’ platform is known for its ability to scale complex interpretation services and has been used to interpret challenging genetic disease cases for various large health systems, academic centers, and research partners.Through this acquisition, health systems will gain the option to use GeneDx’s centralized lab or conduct sequencing at their own facilities while leveraging GeneDx’s data and Fabric Genomics’ AI-powered interpretation platform. The companies believe that this model will lead to faster and earlier diagnoses of genetic diseases, improved patient outcomes, and reduced costs for healthcare systems.Expanding Market ReachThe acquisition will also enable GeneDx to expand its market reach into several key areas:NICU Genomic Testing: The companies aim to increase the use of rapid whole genome sequencing in NICUs, where it has the potential to reduce diagnostic time and costs and improve outcomes for infants.The companies aim to increase the use of rapid whole genome sequencing in NICUs, where it has the potential to reduce diagnostic time and costs and improve outcomes for infants
GAITHERSBURG, Md.-(BUSINESS WIRE)- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, announced today they have been named to Fast Company's prestigious list of the World's Most Innovative Companies of 2025, and recognized as the No. 2 in the Biotech category.
GeneDx Showcases Groundbreaking Genomic Research at 2025 ACMG Annual Clinical Genetics Meeting